Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains

New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori : A first Italian experience in clinical practice

(2017) Antonio Tursi et al.   HELICOBACTER

The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults

(2016) Carlo A. Fallone et al.   GASTROENTEROLOGY

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of Helicobacter pylori

(2016) Giulia Fiorini et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

In vitroantimicrobial susceptibility ofHelicobacter pylorito nine antibiotics currently used in Central Italy

(2015) Mara Di Giulio et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication ofHelicobacter pylori

(2014) J. C. Delchier et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Problem of Helicobacter pylori Resistance to Antibiotics: A Systematic Review in Latin America

(2014) M Constanza Camargo et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Treatment for H. pylori Infection

(2013) Nimish Vakil et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection

(2012) Giulia Fiorini et al.   Clinical Gastroenterology and Hepatology

Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption

(2012) Francis Megraud et al.   GUT

The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy

(2012) Francis Mégraud   Therapeutic Advances in Gastroenterology

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial

(2011) Peter Malfertheiner et al.   LANCET